BSE filing, NSE: PARMAX. Summary written from the filing by ALFA Finder's alert engine.
Parmax Pharma Ltd: key numbers
- Share price
- ₹135.05
- Market cap
- ₹50.53 Cr
- Revenue (annual)
- ₹12.11 Cr
- Net profit (annual)
- ₹-4.16 Cr
- P/E (TTM)
- -42.3×Sector 46.1×
- Promoter holding
- 64.66%+33.86% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Parmax Pharma Ltd
All →Parmax Pharma Management Change
Parmax Pharma's independent director Ami Shah resigned effective October 28, 2026. The exit follows a change in management and control of the company.
Parmax Pharma Management Change
Parmax Pharma Ltd announced the resignation of Mr. Nikhil Uchat as an Independent Director of the Company, effective October 08, 2026.
Parmax Pharma Annual General Meeting
Parmax Pharma Ltd conducted its 32nd Annual General Meeting on September 29, 2026, covering routine business including financial statement adoption and board appointments.
Parmax Pharma Adverse Business Impact
Parmax Pharma reported a major fire incident at its Rajkot plant on September 28, 2026. Two employees were injured, and the company is currently assessing the financial damage.
Parmax Pharma Other Announcement
Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.
Parmax Pharma Annual General Meeting
Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.